Please login to the form below

Not currently logged in
Email:
Password:

fulranumab

This page shows the latest fulranumab news and features for those working in and with pharma, biotech and healthcare.

Lilly, Pfizer say NGF drug works in back pain too

Lilly, Pfizer say NGF drug works in back pain too

The class has a lengthy list of discontinued candidates, mainly due to safety issues, including Johnson &John/Amgen’s fulranumab and candidates from AstraZeneca and AbbVie.

Latest news

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics